A baby named KJ in the US is one of the first to receive CRISPR gene-editing therapy for a rare genetic disorder called CPS1 deficiency, which affects ammonia levels in the blood. The treatment has shown promising initial results, reducing KJ's reliance on medication. However, experts caution about the challenges of scaling CRISPR therapies and the potential side effects. Teljes cikk (Euronews.com)